Skip to main content
Top
Published in: Clinical and Experimental Nephrology 4/2010

01-08-2010 | Original Article

Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study

Authors: Yukiko Hasuike, Hiroshi Nonoguchi, Masanori Tokuyama, Mai Ohue, Takanori Nagai, Mana Yahiro, Masayoshi Nanami, Yoshinaga Otaki, Takeshi Nakanishi

Published in: Clinical and Experimental Nephrology | Issue 4/2010

Login to get access

Abstract

Background

The mortality in end-stage renal disease patients with dialysis remains high. Serum ferritin is a useful surrogated marker of iron storage. It has not been elucidated whether the ferritin level can predict the prognosis of patients with dialysis but without obvious inflammation. To clarify whether the ferritin level is involved in the prognosis in dialyzed patients, we investigated the relation between ferritin level and mortality in hemodialyzed patients during long-term follow-up.

Methods

Ninety stable hemodialyzed patients were enrolled and followed for 107 months. Serum ferritin and related factors (dialysis, nutrition, iron metabolism, inflammation and oxidative stress) were measured and used for statistical analysis. Survival analysis of death for ferritin as a predictive variable was performed.

Results

A relatively high level of serum ferritin (≥100 ng/ml) was associated with poor prognosis after adjustment for basic factors and C reactive protein (hazard ratio, 4.18). Hemoglobin-stratified Kaplan-Meier analysis showed that the prognosis for the high ferritin-low hemoglobin group was significantly poor.

Conclusion

This study suggests that the ferritin level is closely associated with high mortality in hemodialyzed patients. Further studies investigating the pathological role of iron storage on survival of hemodialyzed patients with large populations are needed.
Literature
1.
go back to reference Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis. 2001;37:564–72.CrossRefPubMed Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis. 2001;37:564–72.CrossRefPubMed
2.
go back to reference Gejyo F, Saito A, Akizawa T, Akiba T, Sakai T, Suzuki M, et al. Japanese Society for Dialysis Therapy 2004. Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial. 2004;8(6):443–59.CrossRefPubMed Gejyo F, Saito A, Akizawa T, Akiba T, Sakai T, Suzuki M, et al. Japanese Society for Dialysis Therapy 2004. Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial. 2004;8(6):443–59.CrossRefPubMed
3.
go back to reference Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med. 1976;15(2):212–6.CrossRefPubMed Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med. 1976;15(2):212–6.CrossRefPubMed
4.
go back to reference Jenq CC, Hsu CW, Huang WH, Chen KH, Lin JL, Lin-Tan DT. Serum ferritin levels predict all-cause and infection-cause 1-year mortality in diabetic patients on maintenance hemodialysis. Am J Med Sci. 2009;337(3):188–94.CrossRefPubMed Jenq CC, Hsu CW, Huang WH, Chen KH, Lin JL, Lin-Tan DT. Serum ferritin levels predict all-cause and infection-cause 1-year mortality in diabetic patients on maintenance hemodialysis. Am J Med Sci. 2009;337(3):188–94.CrossRefPubMed
5.
go back to reference Otaki Y, Nakanishi T, Hasuike Y, Moriguchi R, Nanami M, Hama Y, et al. Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis. Am J Kidney Dis. 2004;43(6):1030–9.CrossRefPubMed Otaki Y, Nakanishi T, Hasuike Y, Moriguchi R, Nanami M, Hama Y, et al. Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis. Am J Kidney Dis. 2004;43(6):1030–9.CrossRefPubMed
6.
go back to reference Nanami M, Ookawara T, Otaki Y, Ito K, Moriguchi R, Miyagawa K, et al. Tumor necrosis factor-alpha-induced iron sequestration and oxidative stress in human endothelial cells. Arterioscler Thromb Vasc Biol. 2005;25(12):2495–501.CrossRefPubMed Nanami M, Ookawara T, Otaki Y, Ito K, Moriguchi R, Miyagawa K, et al. Tumor necrosis factor-alpha-induced iron sequestration and oxidative stress in human endothelial cells. Arterioscler Thromb Vasc Biol. 2005;25(12):2495–501.CrossRefPubMed
7.
go back to reference Ford GC, Harrison PM, Rice DW, Smith JM, Treffry A, White JL, et al. Ferritin: design and formation of an iron-storage molecule. Philos Trans R Soc Lond B Biol Sci. 1984;304(1121):551–65.CrossRefPubMed Ford GC, Harrison PM, Rice DW, Smith JM, Treffry A, White JL, et al. Ferritin: design and formation of an iron-storage molecule. Philos Trans R Soc Lond B Biol Sci. 1984;304(1121):551–65.CrossRefPubMed
8.
go back to reference Hasuike Y, Nonoguchi H, Tokuyama M, Hata R, Kitamura R, Hori K, et al. The pathological role of aminolevulinate in uremic patients. Ther Apher Dial. 2010 (in press). Hasuike Y, Nonoguchi H, Tokuyama M, Hata R, Kitamura R, Hori K, et al. The pathological role of aminolevulinate in uremic patients. Ther Apher Dial. 2010 (in press).
9.
go back to reference Yamanishi H, Iyama S, Yamaguchi Y, Kanakura Y, Iwatani Y. Relation between iron content of serum ferritin and clinical status factors extracted by factor analysis in patients with hyperferritinemia. Clin Biochem. 2002;35(7):523–9.CrossRefPubMed Yamanishi H, Iyama S, Yamaguchi Y, Kanakura Y, Iwatani Y. Relation between iron content of serum ferritin and clinical status factors extracted by factor analysis in patients with hyperferritinemia. Clin Biochem. 2002;35(7):523–9.CrossRefPubMed
11.
go back to reference Pietrangelo A. Physiology of iron transport and the hemochromatosis gene. Am J Physiol Gastrointest Liver Physiol. 2002;282:G403–14.PubMed Pietrangelo A. Physiology of iron transport and the hemochromatosis gene. Am J Physiol Gastrointest Liver Physiol. 2002;282:G403–14.PubMed
12.
go back to reference Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070–80.CrossRefPubMed Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070–80.CrossRefPubMed
13.
go back to reference Benkhedda K, L’abbé MR, Cockell KA. Effect of Ca on iron absorption in women with marginal iron status. Br J Nutr. 2009;28:1–7. Benkhedda K, L’abbé MR, Cockell KA. Effect of Ca on iron absorption in women with marginal iron status. Br J Nutr. 2009;28:1–7.
Metadata
Title
Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study
Authors
Yukiko Hasuike
Hiroshi Nonoguchi
Masanori Tokuyama
Mai Ohue
Takanori Nagai
Mana Yahiro
Masayoshi Nanami
Yoshinaga Otaki
Takeshi Nakanishi
Publication date
01-08-2010
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2010
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0288-x

Other articles of this Issue 4/2010

Clinical and Experimental Nephrology 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.